Cannabidiol reverses the mCPP-induced increase in marble-burying behavior

Fundamental and Clinical Pharmacology

Volumn 28, Issue 5, 2014, Pages 544-550

  Nardo, Mirella ^a   Casarotto, Plinio C ^a   Gomes, Felipe V ^a   Guimarães, Francisco S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

mCPP; Cannabidiol; Marble burying; Obsessive compulsive

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; CANNABIDIOL; FLUOXETINE; 1-(3-CHLOROPHENYL)PIPERAZINE; ANXIOLYTIC AGENT; PIPERAZINE DERIVATIVE; SEROTONIN AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR ASSESSMENT; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPULSION; CONTROLLED STUDY; DRUG EFFECT; EXPLORATORY BEHAVIOR; LOCOMOTION; MALE; MARBLE BURYING TEST; MOUSE; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; ANIMAL; ANIMAL BEHAVIOR; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; STEREOTYPIC MOVEMENT DISORDER;

ANIMALS; ANTI-ANXIETY AGENTS; BEHAVIOR, ANIMAL; CANNABIDIOL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; PIPERAZINES; SEROTONIN RECEPTOR AGONISTS; STEREOTYPIC MOVEMENT DISORDER;

EID: 84927574488     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12051     Document Type: Article

References (33)

1. Abramowitz J.S., Taylor S., McKay D. Obsessive-compulsive disorder. Lancet (2009) 374 491-499.
2. Greist J.H., Bandelow B., Hollander E. et al. WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectr. (2003) 8 7-16.
3. Zohar J., Chopra M., Sasson Y., Amiaz R., Amital D. Obsessive compulsive disorder: serotonin and beyond. World J. Biol. Psychiatry (2000) 1 92-100.
4. Stein D.J. Advances in the neurobiology of obsessive-compulsive disorder. Implications for conceptualizing putative obsessive-compulsive and spectrum disorders. Psychiatr. Clin. North Am. (2000) 23 545-562.
5. Broocks A., Pigott T.A., Hill J.L. et al. Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results. Psychiatry Res. (1998) 79 11-20.
6. Erzegovesi S., Cavallini M.C., Cavedini P., Diaferia G., Locatelli M., Bellodi L. Clinical predictors of drug response in obsessive-compulsive disorder. J. Clin. Psychopharmacol. (2001) 21 488-492.
7. Gross-Isseroff R., Cohen R., Sasson Y., Voet H., Zohar J. Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan. Neuropsychobiology (2004) 50 200-205.
8. Khanna S., John J.P., Reddy L.P. Neuroendocrine and behavioral responses to mCPP in Obsessive-Compulsive Disorder. Psychoneuroendocrinology (2001) 26 209-223.
9. Kennett G.A., Whitton P., Shah K., Curzon G. Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. Eur. J. Pharmacol. (1989) 164 445-454.
10. Erzegovesi S., Martucci L., Henin M., Bellodi L. Low versus standard dose mCPP challenge in obsessive-compulsive patients. Neuropsychopharmacology (2001) 24 31-36.
11. Tsaltas E., Kontis D., Chrysikakou S. et al. Reinforced spatial alternation as an animal model of obsessive-compulsive disorder (OCD): investigation of 5-HT2C and 5-HT1D receptor involvement in OCD pathophysiology. Biol. Psychiatry (2005) 57 1176-1185.
12. Kreiss D.S., Coffman C.F., Fiacco N.R. et al. Ritualistic Chewing Behavior induced by mCPP in the rat is an animal model of Obsessive Compulsive Disorder. Pharmacol. Biochem. Behav. (2013) 104 119-124.
13. Guimaraes F.S., Chiaretti T.M., Graeff F.G., Zuardi A.W. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (1990) 100 558-559.
14. Resstel L.B., Tavares R.F., Lisboa S.F., Joca S.R., Correa F.M., Guimaraes F.S. 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br. J. Pharmacol. (2009) 156 181-188.
15. Zanelati T.V., Biojone C., Moreira F.A., Guimaraes F.S., Joca S.R. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br. J. Pharmacol. (2010) 159 122-128.
16. Casarotto P.C., Gomes F.V., Resstel L.B., Guimaraes F.S. Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors. Behav. Pharmacol. (2010) 21 353-358.
17. Njunge K., Handley S.L. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol. Biochem. Behav. (1991) 38 63-67.
18. Njung'e K., Handley S.L. Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents. Br. J. Pharmacol. (1991) 104 105-112.
19. Thomas A., Burant A., Bui N., Graham D., Yuva-Paylor L.A., Paylor R. Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. Psychopharmacology (2009) 204 361-373.
20. Umathe S.N., Manna S.S., Jain N.S. Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice. Behav. Brain Res. (2011) 223 125-134.
21. Graf M., Kantor S., Anheuer Z.E., Modos E.A., Bagdy G. m-CPP-induced self-grooming is mediated by 5-HT2C receptors. Behav. Brain Res. (2003) 142 175-179.
22. Hollander E., DeCaria C., Gully R. et al. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder. Psychiatry Res. (1991) 36 1-17.
23. Zohar J., Insel T.R., Zohar-Kadouch R.C., Hill J.L., Murphy D.L. Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. Arch. Gen. Psychiatry (1988) 45 167-172.
24. Koran L.M., Pallanti S., Quercioli L. Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder. Eur. Neuropsychopharmacol. (2001) 11 169-172.
25. Pian K.L., Westenberg H.G., van Megen H.J., den Boer J.A. Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder. Psychopharmacology (1998) 140 365-370.
26. Stern L., Zohar J., Cohen R., Sasson Y. Treatment of severe, drug resistant obsessive compulsive disorder with the 5HT1D agonist sumatriptan. Eur. Neuropsychopharmacol. (1998) 8 325-328.
27. Gomes F.V., Casarotto P.C., Resstel L.B., Guimaraes F.S. Facilitation of CB1 receptor-mediated neurotransmission decreases marble burying behavior in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry (2011) 35 434-438.
28. Kinsey S.G., O'Neal S.T., Long J.Z., Cravatt B.F., Lichtman A.H. Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol. Biochem. Behav. (2011) 98 21-27.
29. Fineberg N.A., Chamberlain S.R., Hollander E., Boulougouris V., Robbins T.W. Translational approaches to obsessive-compulsive disorder: from animal models to clinical treatment. Br. J. Pharmacol. (2011) 164 1044-1061.
30. Fineberg N.A., Potenza M.N., Chamberlain S.R. et al. Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. Neuropsychopharmacology (2010) 35 591-604.
31. Joel D. Current animal models of obsessive compulsive disorder: a critical review. Prog. Neuropsychopharmacol. Biol. Psychiatry (2006) 30 374-388.
32. Korff S., Harvey B.H. Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology. Psychiatr. Clin. North Am. (2006) 29 371-390.
33. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. (2002) 23 238-245.